Korro Bio shares Analyst Day slides

Korro Bio, Inc. reported that it hosted a virtual Analyst Day on January 27, 2026.

Rhea-AI Filing Summary

Korro Bio, Inc. reported that it hosted a virtual Analyst Day on January 27, 2026. The company made selected presentation slides from this event publicly available by attaching them as an exhibit to this report. These slides are intended to provide additional background and strategic information about Korro Bio’s business for analysts and investors.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Korro Bio, Inc. (KRRO) disclose in this 8-K?

Korro Bio, Inc. disclosed that it held a virtual Analyst Day on January 27, 2026 and filed selected presentation slides from that event as an exhibit.

What is included in Exhibit 99.1 for Korro Bio, Inc. (KRRO)?

Exhibit 99.1 contains selected slides from Korro Bio, Inc.’s Analyst Day presentation dated January 27, 2026.

When did Korro Bio, Inc. hold its Analyst Day event?

Korro Bio, Inc. held its virtual Analyst Day on January 27, 2026.

Who signed the Korro Bio, Inc. (KRRO) report related to the Analyst Day?

The report was signed by Ram Aiyar, who is the President, Chief Executive Officer and Interim Chief Financial Officer of Korro Bio, Inc.

Does this Korro Bio, Inc. (KRRO) report include financial results?

The report highlights the Analyst Day and the related presentation slides; it does not present financial results in the text provided.

What stock exchange lists Korro Bio, Inc. (KRRO) common stock?

Korro Bio, Inc.’s common stock, par value $0.001 per share, is listed on The Nasdaq Capital Market under the trading symbol KRRO.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/27/2026 - 09:15 AM EST Learn about SEC filing dates

0001703647false00017036472026-01-272026-01-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 27, 2026

Korro Bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-39062	47-2324450
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
60 First Street, 2nd floor, Suite 250 Cambridge, MA		02141
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 468-1999

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		KRRO		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On January 27, 2026, Korro Bio, Inc. hosted a virtual Analyst Day. A copy of certain presentation slides is filed as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Selected Slides from Analyst Day Presentation of Korro Bio, Inc., dated January 27, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	KORRO BIO, INC.
Date: January 27, 2026	By:	/s/ Ram Aiyar
		Name: Ram Aiyar
		Title: President and Chief Executive Officer and Interim Chief Financial Officer